Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
- 8 September 2015
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 16 (13), 1344-1354
- https://doi.org/10.1016/s1470-2045(15)00198-9
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Effect and Safety of Interferon for Hepatocellular Carcinoma: A Systematic Review and Meta-AnalysisPLOS ONE, 2013
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trialJournal of Hepatology, 2012
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinomaEuropean Journal of Cancer, 2012
- Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in ItalyJournal of Hepatology, 2011
- Management of hepatocellular carcinoma: An updateJournal of Hepatology, 2011
- The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targetsSeminars in Cancer Biology, 2011
- Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinomaHepatology International, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: Implications for surveillance studies and new adjuvant therapiesLiver Transplantation, 2008
- Resection and Liver Transplantation for Hepatocellular CarcinomaSeminars in Liver Disease, 2005